1-(3-chlorophenyl)piperazine has been researched along with Anxiety Neuroses in 11 studies
1-(3-chlorophenyl)piperazine: supposed metabolite of TRAZODONE; RN given refers to parent cpd; structure
1-(3-chlorophenyl)piperazine : A N-arylpiperazine that is piperazine carrying a 3-chlorophenyl substituent at position 1. It is a metabolite of the antidepressant drug trazodone.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The behavioral and neuroendocrine effects of meta-chlorophenylpiperazine (m-CPP), a serotonergic agonist, were compared with the effects of caffeine, an adenosine antagonist, in panic disorder patients." | 9.07 | Anxiogenic effects of m-CPP in patients with panic disorder: comparison to caffeine's anxiogenic effects. ( Geraci, MF; Klein, E; Murphy, DL; Uhde, TW; Zohar, J, 1991) |
| "The behavioral and neuroendocrine effects of meta-chlorophenylpiperazine (m-CPP), a serotonergic agonist, were compared with the effects of caffeine, an adenosine antagonist, in panic disorder patients." | 5.07 | Anxiogenic effects of m-CPP in patients with panic disorder: comparison to caffeine's anxiogenic effects. ( Geraci, MF; Klein, E; Murphy, DL; Uhde, TW; Zohar, J, 1991) |
| "Panic attacks were significantly more provoked in patients with PD (85%), but not in patients with gSAD (14%) as compared to healthy controls (0%)." | 2.73 | Behavioural effects of rapid intravenous administration of meta-chlorophenylpiperazine (m-CPP) in patients with generalized social anxiety disorder, panic disorder and healthy controls. ( Fiselier, J; Van der Wee, NJ; Van Veen, JF; Van Vliet, IM; Westenberg, HG, 2007) |
| " Thus, it may be important to elucidate functional changes in these 5-HT receptor subtypes in brain regions including the amygdala under the chronic administration of SSRIs to understand the anxiolytic mechanism of SSRIs." | 2.43 | [Role of the serotonergic nervous system in anxiety disorders and the anxiolytic mechanism of selective serotonin reuptake inhibitors]. ( Hiraoka, S; Imanishi, T; Yamauchi, M, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (63.64) | 18.2507 |
| 2000's | 4 (36.36) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Klaassen, T | 1 |
| Riedel, WJ | 1 |
| van Praag, HM | 4 |
| Menheere, PP | 1 |
| Griez, E | 1 |
| Leveleki, C | 1 |
| Sziray, N | 1 |
| Levay, G | 1 |
| Barsvári, B | 1 |
| Soproni, K | 1 |
| Mikics, E | 1 |
| Haller, J | 1 |
| Yamauchi, M | 1 |
| Hiraoka, S | 1 |
| Imanishi, T | 1 |
| Van Veen, JF | 1 |
| Van der Wee, NJ | 1 |
| Fiselier, J | 1 |
| Van Vliet, IM | 1 |
| Westenberg, HG | 1 |
| Goddard, AW | 1 |
| Woods, SW | 1 |
| Money, R | 1 |
| Pande, AC | 1 |
| Charney, DS | 1 |
| Goodman, WK | 1 |
| Heninger, GR | 1 |
| Price, LH | 1 |
| Kahn, RS | 3 |
| Wetzler, S | 3 |
| Asnis, GM | 3 |
| Kling, MA | 1 |
| Suckow, RF | 1 |
| Klein, E | 1 |
| Zohar, J | 1 |
| Geraci, MF | 1 |
| Murphy, DL | 2 |
| Uhde, TW | 1 |
| Korn, M | 1 |
| Benjamin, D | 1 |
| Lal, H | 1 |
| Meyerson, LR | 1 |
| Bihari, K | 1 |
| Pato, MT | 1 |
| Hill, JL | 1 |
| Kalus, O | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Preoperative Anxiety's Incidence and Related Factors in Surgical Patients[NCT03162692] | 2,000 participants (Anticipated) | Observational | 2017-04-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for 1-(3-chlorophenyl)piperazine and Anxiety Neuroses
| Article | Year |
|---|---|
[Role of the serotonergic nervous system in anxiety disorders and the anxiolytic mechanism of selective serotonin reuptake inhibitors].
Topics: Animals; Anxiety Disorders; Fluvoxamine; Humans; Piperazines; Receptor, Serotonin, 5-HT1A; Receptor, | 2006 |
5 trials available for 1-(3-chlorophenyl)piperazine and Anxiety Neuroses
| Article | Year |
|---|---|
Neuroendocrine response to meta-chlorophenylpiperazine and ipsapirone in relation to anxiety and aggression.
Topics: Adolescent; Adrenocorticotropic Hormone; Adult; Aged; Aggression; Anxiety Disorders; Cross-Over Stud | 2002 |
Behavioural effects of rapid intravenous administration of meta-chlorophenylpiperazine (m-CPP) in patients with generalized social anxiety disorder, panic disorder and healthy controls.
Topics: Adult; Anxiety Disorders; Female; Growth Hormone; Humans; Hydrocortisone; Injections, Intravenous; M | 2007 |
Effects of the CCK(B) antagonist CI-988 on responses to mCPP in generalized anxiety disorder.
Topics: Adult; Affect; Analysis of Variance; Anti-Anxiety Agents; Anxiety Disorders; Blood Pressure; Female; | 1999 |
Anxiogenic effects of m-CPP in patients with panic disorder: comparison to caffeine's anxiogenic effects.
Topics: Adult; Anxiety Disorders; Arousal; Brain; Caffeine; Double-Blind Method; Female; Humans; Hydrocortis | 1991 |
Serotonin receptor sensitivity and aggression.
Topics: Adult; Aggression; Anger; Anxiety Disorders; Depressive Disorder; Double-Blind Method; Female; Human | 1991 |
5 other studies available for 1-(3-chlorophenyl)piperazine and Anxiety Neuroses
| Article | Year |
|---|---|
Pharmacological evaluation of the stress-induced social avoidance model of anxiety.
Topics: Animals; Anti-Anxiety Agents; Anxiety Disorders; Brain; Buspirone; Chlordiazepoxide; Diazepam; Disea | 2006 |
Pituitary hormone responses to meta-chlorophenylpiperazine in panic disorder and healthy control subjects.
Topics: Adrenocorticotropic Hormone; Adult; Agoraphobia; Anxiety Disorders; Female; Humans; Male; Panic; Pip | 1991 |
The effects of 5-HT1B characterizing agents in the mouse elevated plus-maze.
Topics: Animals; Anti-Anxiety Agents; Anxiety Disorders; Chlordiazepoxide; Male; Mice; Mice, Inbred Strains; | 1990 |
Neurologic soft signs in obsessive-compulsive disorder.
Topics: Adult; Anxiety Disorders; Central Nervous System Diseases; Clomipramine; Clonidine; Depressive Disor | 1991 |
Hypersensitivity to m-chlorophenylpiperazine in a subject with subclinical panic attacks.
Topics: Administration, Oral; Anxiety Disorders; Dose-Response Relationship, Drug; Female; Humans; Middle Ag | 1990 |